Prostate Cancer

Panelists and audience members at the recent AUA “crossfire” debate on focal therapy show why the treatment is so controversial.

The cell surface amino acid glypican-1 (GPC-1) represents a potential new biomarker for prostate cancer, said Jonathan Henderson, MD, at the AUA annual meeting.

A novel metric for evaluating post-prostatectomy outcomes could support quality improvement initiatives for optimizing patient recovery.

Recently published research on a novel chemotherapy-immunotherapy combination is “exciting for multiple reasons,” says one expert.

A new study assesses how a biopsy-based gene test impacts prostate cancer treatment recommendations in three high-volume practices.

Products in the pipeline for prostate cancer, bladder cancer, and much more.

Post-radical prostatectomy radiation therapy in patients at risk of prostate cancer recurrence is on the wane in the U.S., despite evidence and guidelines supporting the practice, recently published research indicates.

Biomarker models to predict disease progression in prostate cancer have a promising future, but at present, they have not fully justified their claimed clinical utilities, according to the authors of an independent review and analysis of the literature.

Other products featured include a spacer system to protect men undergoing PCa radiotherapy, a pelvic floor exercise app, and more.

I am more optimistic that we will find a way to treat those who truly need to be treated and follow those unlikely to die from their disease.

Placement of a nerve “wrap” around the neurovascular bundle during nerve-sparing robot-assisted radical prostatectomy appears to accelerate the early restoration of continence and potency following surgery, a recently published study has shown.

Products in the pipeline for prostate cancer, bladder cancer, stress urinary incontinence, chronic prostatitis/chronic pelvic pain syndrome, hypoactive sexual desire disorder.

To help you maximize your AUA experience, Urology Times’ editorial board and other thought leaders have pored over hundreds of abstracts to identify the key trends and can’t-miss research from this year’s meeting.

Statins may improve outcomes in hormone-sensitive prostate cancer, and one possible mechanism responsible may have been discovered.

The findings could help clinicians differentiate between slow-growing and aggressive tumors

The FDA has granted clearance to a hydrogel spacer for prostate cancer patients undergoing radiotherapy.

Final analysis of a phase III trial shows abiraterone acetate (ZYTIGA) plus prednisone extended overall survival compared to placebo plus prednisone in chemotherapy-naive men with mCRPC.

Recent phase II results point to the efficacy of the prostate cancer agent enzalutamide (XTANDI) when compared with bicalutamide (Casodex).

Men with prostate cancer who meet the criteria for active surveillance and undergo delayed radical prostatectomy after a period of active surveillance do not have a higher risk of adverse pathology compared with men with similar pre-treatment biopsy features who undergo immediate prostatectomy.

Charles J. Ryan, MD, recently presented the final analysis of the COU-AA-302 study of abiraterone acetate (ZYTIGA) versus placebo.

Christopher Amling, MD, describes strategies to reduce skeletal-related morbidity, including lifestyle changes, calcium and vitamin D supplementation, and pharmacologic therapy.

An iodine-125 low-dose-rate brachytherapy boost outperformed dose-escalated external beam radiotherapy boost in achieving biochemical progression-free survival in men with unfavorable risk prostate cancer, according to results of a recent multicenter trial.

The major organizations representing urologists are continuing their push for congressional approval of legislation designed to reform the operations of the U.S. Preventive Services Task Force, which in May 2012 recommended against PSA-based screening for prostate cancer.

Results presented at the EAU Annual Congress bolster the Prolaris test’s efficacy in determining disease aggressiveness.

Other highly read UT articles this month include a large comparison of robotic and open RP, answers to your questions about coding for prostate biopsy, and several studies about risks for low and high T.

The AUA, Large Urology Group Practice Association (LUGPA), and American Association of Clinical Urologists (AACU) would like to see the U.S. Preventive Services Task Force (USPSTF) revamp the methods it uses to develop recommendations on prostate cancer screening and other preventive care, and the three associations are now backing legislation that would do just that.

New, large-scale studies on active surveillance, IMRT complications, and robotic versus open prostatectomy were among the highlights of this year’s Genitourinary Cancers Symposium.

The review “represents the best available evidence for the morbidity and cost profile” of robot-assisted versus open radical prostatectomy, says one of the study’s authors.

Multiparametric MRI of the prostate with subsequent targeted biopsy shows promise for improving the identification of men on active surveillance for low-risk prostate cancer who require definitive treatment, according to researchers from the Vancouver Prostate Centre, Vancouver, BC.

Urologists with higher surgical volumes, especially in robotic procedures, are more likely to recommend immediate treatment than active surveillance in men with low-risk prostate cancer, according to a recent study.